Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d

被引:4
作者
Sciascia, Savino [1 ,2 ,3 ]
Bloch, Rory [4 ]
O'Malley, Tyler [4 ]
Kammesheidt, Anja [4 ]
Alexander, Roberta Vezza [4 ]
机构
[1] Univ Turin, Univ Ctr Excellence Nephrol, Rheumatol & Rare Dis Nephrol & Dialysis Unit, Turin, Italy
[2] Univ Turin, San Giovanni Bosco Hub Hosp, Ctr Immuno Rheumatol & Rare Dis CMID, Coordinating Ctr Interreg Network Rare Dis Piedmo, Turin, Italy
[3] Dept Clin Biol Sci Univ Turin, Dept Clin, Turin, Italy
[4] Exagen Inc, Vista, CA 92801 USA
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
antiphospholipid antibodies; antiphospholipid syndrome; biomarkers; persistency; cell-bound complement activation products; PC4d; COMPLEMENT ACTIVATION; CLASSIFICATION CRITERIA; DIAGNOSIS;
D O I
10.3389/fimmu.2022.949919
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundClassification criteria for antiphospholipid syndrome (APS) require that antiphospholipid antibody (aPL) positivity is confirmed after at least 12 weeks. We tested the hypothesis that aPL at high titers remain positive while low titers fluctuate over time. As both platelet-bound C4d (PC4d) and aPL are associated with thrombosis in systemic lupus erythematosus (SLE), we also evaluated whether PC4d can aid in APS diagnosis. MethodsData from serum or plasma sent to Exagen's laboratory for routine aPL testing were analyzed. Anti-cardiolipin (aCL) and anti-beta2 glycoprotein-1 antibodies (aB2GP1) were measured by chemiluminescence or ELiA fluorescence enzyme immunoassay; anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) by ELISA; PC4d by flow cytometry. Statistical analysis included descriptive statistics, logistic regression, and Pearson correlation. ResultsMore than 80% of positive samples with aCL and aB2GP1 at high titers - but not low titers - were positive at a retest. Non-criteria aPL (aPS/PT) followed a similar trend. aCL and aB2GP1 measured with two different technologies were highly correlated. PC4d and IgG of the three aPL were at best moderately correlated even when only positive aPL samples were analyzed (coefficient: 0.1917 to 0.2649). ConclusionsHigh titers aPL are often persistently positive, allowing an earlier diagnosis and risk assessment at the time of the initial screening. Conversely, a retest may be necessary for low titers. The high correlation between two methodologies suggests that these findings are independent of assay platform. The low to moderate correlation between PC4d and aPL might suggest a possible additive value to evaluate association with thrombosis in autoimmune diseases.
引用
收藏
页数:7
相关论文
共 28 条
  • [1] Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1002/art.40930, 10.1136/annrheumdis-2018-214819]
  • [2] Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome
    Breen, Karen A.
    Seed, Paul
    Parmar, Kiran
    Moore, Gary W.
    Stuart-Smith, Sara E.
    Hunt, Beverley J.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) : 423 - 429
  • [3] Evaluation of different immunoassays for the detection of antiphospholipid antibodies: Report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies
    Forastfero, R.
    Papalardo, E.
    Watkins, M.
    Nguyen, H.
    Quirbach, C.
    Jaskal, K.
    Kast, M.
    Teodorescu, M.
    Lakos, G.
    Binder, W.
    Shums, Z.
    Nelson, V.
    Norman, G.
    Puig, J.
    Cox, A.
    Vandam, W.
    Hardy, J.
    Pierangeli, S.
    [J]. CLINICA CHIMICA ACTA, 2014, 428 : 99 - 105
  • [4] Diagnosis and Management of the Antiphospholipid Syndrome
    Garcia, David
    Erkan, Doruk
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) : 2010 - 2021
  • [5] Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in Systemic Lupus Erythematosus
    Gartshteyn, Yevgeniya
    Mor, Adam
    Shimbo, Daichi
    Khalili, Leila
    Kapoor, Teja
    Geraldino-Pardilla, Laura
    Alexander, Roberta V.
    Conklin, John
    Dervieux, Thierry
    Askanase, Anca D.
    [J]. CLINICAL IMMUNOLOGY, 2021, 228
  • [6] Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository
    Gkrouzman, Elena
    Sevim, Ecem
    Finik, Jackie
    Andrade, Danieli
    Pengo, Vittorio
    Sciascia, Savino
    Tektonidou, Maria G.
    Ugarte, Amaia
    Chighizola, Cecilia B.
    Belmont, H. Michael
    Lopez-Pedrera, Chary
    Ji, Lanlan
    Fortin, Paul
    Efthymiou, Maria
    de Jesus, Guilherme Ramires
    Branch, D. Ware
    Nalli, Cecilia
    Petri, Michelle
    Rodriguez, Esther
    Cervera, Ricard
    Knight, Jason S.
    Atsumi, Tatsuya
    Willis, Rohan
    Bertolaccini, Maria Laura
    Cohen, Hannah
    Rand, Jacob
    Erkan, Doruk
    [J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (04) : 541 - 547
  • [7] Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
    Hochberg, MC
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1725 - 1725
  • [8] Relation of Platelet C4d with All-Cause Mortality and Ischemic Stroke in Patients with Systemic Lupus Erythematosus
    Kao, Amy H.
    McBurney, Christine A.
    Sattar, Abdus
    Lertratanakul, Apinya
    Wilson, Nicole L.
    Rutman, Sarah
    Paul, Barbara
    Navratil, Jeannine S.
    Scioscia, Andrea
    Ahearn, Joseph M.
    Manzi, Susan
    [J]. TRANSLATIONAL STROKE RESEARCH, 2014, 5 (04) : 510 - 518
  • [9] Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria
    Litvinova, Elena
    Darnige, Luc
    Kirilovsky, Amos
    Burnel, Yann
    de Luna, Gonzalo
    Dragon-Durey, Marie-Agnes
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [10] Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome
    Lonati, Paola Adele
    Scavone, Mariangela
    Gerosa, Maria
    Borghi, Maria Orietta
    Pregnolato, Francesca
    Curreli, Daniele
    Podda, Gianmarco
    Femia, Eti Alessandra
    Barcellini, Wilma
    Cattaneo, Marco
    Tedesco, Francesco
    Meroni, Pier Luigi
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10